Bristol-Myers SquibbBMY

關於Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, licenses, manufactures, and markets prescription medicines, with the vast majority of revenue coming from branded specialty drugs rather than generics or consumer products. Its portfolio is anchored in oncology, hematology, immunology, cardiovascular disease, and, more recently, neuroscience, with franchises spanning oral anticoagulants, multiple myeloma therapies, immuno-oncology checkpoint inhibitors, autoimmune treatments, and cell therapies. The company reports as a single segment but discloses product-level sales, and a small number of blockbuster molecules typically generate the bulk of profit. Because gross margins on patented biologics and small molecules are structurally high, revenue mix across the top franchises is the dominant driver of earnings.

Investors track the loss-of-exclusivity cliff on the largest legacy franchises against the ramp of newer launches, since patent expirations in pharmaceuticals produce steep, non-linear revenue declines. Regulatory exposure is central: FDA and EMA approval outcomes, Medicare drug-price negotiation under the Inflation Reduction Act, and pricing pressure from pharmacy benefit managers all shape the cash-flow profile. Other durable questions include pipeline productivity relative to R&D spend, integration progress on large acquisitions, the pace of business-development deals to replenish the pipeline, capital allocation between dividends, buybacks, and debt reduction, and litigation risk around patents and product liability. Index membership in the S&P 500 and Dow Jones pharmaceutical sub-indices makes it a core holding for large passive vehicles.

The modern company was formed in 1989 through the merger of Bristol-Myers, a consumer-products and pharmaceutical firm with roots in an 1887 drug manufacturer in Clinton, New York, and Squibb Corporation, founded in 1858 by naval surgeon Edward Robinson Squibb. Through the 1990s and 2000s the group divested non-core businesses, including the Clairol hair-care unit, Zimmer orthopedics, and Mead Johnson Nutrition, to concentrate on prescription biopharmaceuticals. Transformative acquisitions include DuPont Pharmaceuticals in 2001, Medarex in 2009, which supplied the antibody platform behind its immuno-oncology franchise, Celgene in 2019, which added the multiple myeloma and hematology portfolio, and MyoKardia in 2020. It is incorporated in Delaware and headquartered in Princeton, New Jersey.

Customers are not patients directly but wholesalers, specialty distributors, integrated health systems, retail pharmacy chains, and government payers, with a small number of U.S. distributors accounting for a very large share of domestic shipments. Revenue is booked when product is shipped, then adjusted for rebates and chargebacks negotiated with pharmacy benefit managers, Medicaid, Medicare Part D, and managed-care organizations, so net pricing can diverge sharply from list prices. Competitive position rests on patent protection, clinical differentiation, physician relationships, and manufacturing scale in biologics and cell therapy. The United States generates the majority of sales, with the balance from Europe, Japan, and other international markets, and it competes primarily with the other large-cap global pharmaceutical companies.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Bristol-Myers Squibb的SEC完整報告 →